<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mov Disord</journal-id><journal-id journal-id-type="iso-abbrev">Mov. Disord</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1531-8257</journal-id><journal-id journal-id-type="publisher-id">MDS</journal-id><journal-title-group><journal-title>Movement Disorders</journal-title></journal-title-group><issn pub-type="ppub">0885-3185</issn><issn pub-type="epub">1531-8257</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27753157</article-id><article-id pub-id-type="pmc">5363377</article-id><article-id pub-id-type="doi">10.1002/mds.26827</article-id><article-id pub-id-type="publisher-id">MDS26827</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Regular Issue Articles</subject><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></subj-group></article-categories><title-group><article-title>Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease</article-title><alt-title alt-title-type="right-running-head">Neuropsychology and DBS</alt-title><alt-title alt-title-type="left-running-head">Tr&#x000f6;&#x02009;&#x02009;&#x0200a;&#x0200a;ster et al</alt-title></title-group><contrib-group><contrib id="mds26827-cr-0100" contrib-type="editor"><name><surname>Espay</surname><given-names>Alberto</given-names></name><degrees>MD, MSc</degrees></contrib><contrib id="mds26827-cr-1100" contrib-type="editor"><name><surname>Erro</surname><given-names>Roberto</given-names></name><degrees>MD</degrees></contrib></contrib-group><contrib-group><contrib id="mds26827-cr-0001" contrib-type="author" corresp="yes"><name><surname>Tr&#x000f6;ster</surname><given-names>Alexander I.</given-names></name><degrees>PhD</degrees><address><email>Alexander.Troster@DignityHealth.org</email></address><xref ref-type="aff" rid="mds26827-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="mds26827-cr-0002" contrib-type="author"><name><surname>Jankovic</surname><given-names>Joseph</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="mds26827-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="mds26827-cr-0003" contrib-type="author"><name><surname>Tagliati</surname><given-names>Michele</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="mds26827-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="mds26827-cr-0004" contrib-type="author"><name><surname>Peichel</surname><given-names>DeLea</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="mds26827-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="mds26827-cr-0005" contrib-type="author"><name><surname>Okun</surname><given-names>Michael S.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="mds26827-aff-0005">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="mds26827-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Clinical Neuropsychology and Barrow Center for Neuromodulation</named-content><institution>Barrow Neurological Institute</institution><named-content content-type="city">Phoenix</named-content><named-content content-type="country-part">Arizona</named-content><country country="US">USA</country></aff><aff id="mds26827-aff-0002"><label><sup>2</sup></label><institution>Baylor College of Medicine, Department of Neurology</institution><named-content content-type="city">Houston</named-content><named-content content-type="country-part">Texas</named-content><country country="US">USA</country></aff><aff id="mds26827-aff-0003"><label><sup>3</sup></label><institution>Cedar&#x02010;Sinai Medical Center, Department of Neurology</institution><named-content content-type="city">Los Angeles</named-content><named-content content-type="country-part">California</named-content><country country="US">USA</country></aff><aff id="mds26827-aff-0004"><label><sup>4</sup></label><institution>St. Jude Medical, Clinical Studies</institution><named-content content-type="city">Plano</named-content><named-content content-type="country-part">Texas</named-content><country country="US">USA</country></aff><aff id="mds26827-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Neurology, Center for Movement Disorders and Neurorestoration</named-content><institution>University of Florida School</institution><named-content content-type="city">Gainesville</named-content><named-content content-type="country-part">Florida</named-content><country country="US">USA</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Corresponding author:</bold> Dr. Alexander I. Tr&#x000f6;ster, Barrow Neurological Institute, 222 West Thomas Rd., Suite 315, Phoenix, AZ 85013; <email>Alexander.Troster@DignityHealth.org</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2017</year></pub-date><volume>32</volume><issue>3</issue><issue-id pub-id-type="doi">10.1002/mds.v32.3</issue-id><issue-title content-type="special-issue-title">Gaps and Controversies in Movement Disorders</issue-title><fpage>433</fpage><lpage>440</lpage><history><date date-type="received"><day>15</day><month>6</month><year>2016</year></date><date date-type="rev-recd"><day>03</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>06</day><month>9</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 International Parkinson and Movement Disorder Society <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:MDS-32-433.pdf"/><abstract><title>ABSTRACT</title><sec id="mds26827-sec-0001"><title>Objective</title><p>The aim of this study was to evaluate the neurobehavioral safety of constant&#x02010;current subthalamic deep brain stimulation and to compare the neuropsychological effects of stimulation versus electrode placement alone.</p></sec><sec id="mds26827-sec-0002"><title>Methods</title><p>A total of 136 patients with Parkinson's disease underwent bilateral subthalamic device implantation in this randomized trial. Patients received stimulation either immediately after device implantation (n&#x02009;=&#x02009;101; active stimulation) or beginning 3 months after surgery (n&#x02009;=&#x02009;35; delayed activation control). Patients were administered neuropsychological tests before, 3, and 12 months after device implantation.</p></sec><sec id="mds26827-sec-0003"><title>Results</title><p>Neuropsychological change in stimulation and control groups were comparable. Within&#x02010;group analyses revealed declines in category and switching verbal fluency in both groups, but only the stimulation group had letter verbal fluency and Stroop task declines. Depression symptom improvements occurred in both groups, but more often in the stimulation group. Letter fluency declines were associated with worse Parkinson's Disease Questionnaire Communication subscale scores. Baseline and 12&#x02010;month comparisons (in the combined group) revealed gains in verbal and visual delayed recall scores and improvement in depression symptoms, but decrements in verbal fluency and Stroop scores.</p></sec><sec id="mds26827-sec-0004"><title>Conclusions</title><p>Constant&#x02010;current bilateral subthalamic stimulation had a good cognitive safety profile except for decrements in verbal fluency and on the Stroop task. These abnormalities are related to device implantation, but stimulation likely had an additive effect. One year after surgery, the cognitive changes did not exert a detrimental effect on quality of life, although letter fluency declines were associated with communication dissatisfaction at 12 months. Improvement in depressive symptom severity appears dependent on stimulation and not placebo or lesion effects. &#x000a9; 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="mds26827-kwd-0001">deep brain stimulation</kwd><kwd id="mds26827-kwd-0002">parkinson's disease</kwd><kwd id="mds26827-kwd-0003">neuropsychological outcomes</kwd><kwd id="mds26827-kwd-0004">somatosensory temporal discrimination</kwd></kwd-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="8"/><word-count count="4810"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>mds26827</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.9 mode:remove_FC converted:23.03.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="mds26827-note-1001"><p>This article was published online on 1 August 2016. After online publication, the footnotes were revised. This notice is included in the online and print versions to indicate that both have been corrected on 24 October 2016.</p></fn><fn id="mds26827-note-0001"><p>
<bold>Relevant conflicts of interests/financial disclosures</bold>: Drs. A.I.T. and M.T. are paid consultants for St. Jude Medical. A.I.T. has served as a consultant and/or on the scientific advisory boards for Medtronic, Boston Scientific, Teva, Takeda, Theravance, and Pfizer. He has received grant/research support from National Institutes of Health, the Michael J. Fox Foundation, the Barrow Neurological Foundation, Glaxo Smith Kline, and Medtronic. A.I.T. has received book royalties from Cambridge University Press and Oxford University Press. M.T. has received honoraria from Medtronic Inc. J.J. is a consultant for Allergan, Chelsea Therapeutics, EMD Serono, Lundbeck Inc., Merz Pharmaceuticals, and Teva Pharmaceutical Industries Ltd; has received grants from Allergan, Allon Therapeutics, Ceregene Inc., Chelsea Therapeutics, Diana Helis Henry Medical Research Foundation, EMD Serono, Huntington's Disease Society of America, Huntington Study Group, Impax Pharmaceuticals, Ipsen Limited, Lundbeck Inc., Michael J. Fox Foundation for Parkinson Research, Medtronic, Merz Pharmaceuticals, National Institutes of Health, National Parkinson Foundation, Neurogen, St. Jude Medical Neuromodulation Division, Teva Pharmaceutical Industries Ltd, University of Rochester, and the Parkinson Study Group; and has received royalties from Elsevier, Lippincott Williams and Wilkins, and UpToDate. M.S.O. serves as a consultant for the National Parkinson Foundation and has received research grants from National Institutes of Health, National Parkinson Foundation, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann&#x02010;Strauss Foundation, the Tourette Syndrome Association, and the University of Florida Foundation. M.S.O. has previously received honoraria, but in the past &#x0003e;60 months has received no support from industry. M.S.O. has received royalties for publications with Demos, Manson, Amazon, Smashwords, Books4Patients, and Cambridge (movement disorders books). M.S.O. is an associate editor for the <italic>New England Journal of Medicine Journal Watch Neurology</italic>. M.S.O. has participated in Continuing Medical Education and educational activities on movement disorders (in the past 36) months sponsored by PeerView, Prime, Quantia, Henry Stewart, and by Vanderbilt University. The institution and not M.S.O. receives grants from Medtronic, Abbvie, and Adanced Neuromodulation Systems/St. Jude, and the PI has no financial interest in these grants. M.S.O. has participated as a site principal investigator and/or co&#x02010;investigator for several National Institutes of Health, foundation, and industry sponsored trials over the years but has not received honoraria. D.P. is an employee of St. Jude Medical Inc.</p></fn></fn-group></notes></front><body><p>Several randomized trials have shown voltage&#x02010;controlled subthalamic deep brain stimulation (STN DBS) devices to be superior to best medical therapy (BMT) in alleviating the motor symptoms of Parkinson's disease (PD) and in addressing levodopa&#x02010;related motor therapy complications (eg, dyskinesias) as well as in improving health&#x02010;related quality of life (QOL).<xref rid="mds26827-bib-0001" ref-type="ref">1</xref>, <xref rid="mds26827-bib-0002" ref-type="ref">2</xref>, <xref rid="mds26827-bib-0003" ref-type="ref">3</xref> Significant gains in QOL have been observed after DBS in comparison to BMT even in younger persons with PD who have previously experienced motor complications.<xref rid="mds26827-bib-0004" ref-type="ref">4</xref> A recent trial showed that constant current STN stimulation also improved motor function and QOL.<xref rid="mds26827-bib-0005" ref-type="ref">5</xref>
</p><p>Despite its positive impact on QOL and motor control, STN DBS has potential side effects, for example, mild, circumscribed, and often transient declines in cognition.<xref rid="mds26827-bib-0002" ref-type="ref">2</xref>, <xref rid="mds26827-bib-0003" ref-type="ref">3</xref>, <xref rid="mds26827-bib-0006" ref-type="ref">6</xref>, <xref rid="mds26827-bib-0007" ref-type="ref">7</xref>, <xref rid="mds26827-bib-0008" ref-type="ref">8</xref>, <xref rid="mds26827-bib-0009" ref-type="ref">9</xref>, <xref rid="mds26827-bib-0010" ref-type="ref">10</xref> Although memory, attention, and executive functions can be impacted by STN DBS, the most consistent (albeit not universal) declines involve verbal fluency.<xref rid="mds26827-bib-0011" ref-type="ref">11</xref>, <xref rid="mds26827-bib-0012" ref-type="ref">12</xref>, <xref rid="mds26827-bib-0013" ref-type="ref">13</xref>, <xref rid="mds26827-bib-0014" ref-type="ref">14</xref> Such declines occur in 25% to 50% of patients,<xref rid="mds26827-bib-0015" ref-type="ref">15</xref>, <xref rid="mds26827-bib-0016" ref-type="ref">16</xref> can persist for 3 to 5 years,<xref rid="mds26827-bib-0016" ref-type="ref">16</xref>, <xref rid="mds26827-bib-0017" ref-type="ref">17</xref> and might even worsen between 5 and 8 years after surgery.<xref rid="mds26827-bib-0018" ref-type="ref">18</xref>
</p><p>The neuropsychological effects of constant current DBS have not been documented. This study supplements the original study report<xref rid="mds26827-bib-0005" ref-type="ref">5</xref> by providing detailed neuropsychological outcome data. The study design facilitates the evaluation of competing explanations for verbal fluency decrements after STN DBS, for example, that verbal fluency decrements might represent a microlesion or implantation effect rather than a stimulation effect<xref rid="mds26827-bib-0019" ref-type="ref">19</xref> even though high but not low frequency stimulation may be associated with fluency decrements.<xref rid="mds26827-bib-0020" ref-type="ref">20</xref> The study also tested the hypothesis that verbal fluency decrements are a function of reduction in dopaminergic medication after DBS.<xref rid="mds26827-bib-0021" ref-type="ref">21</xref> The current study was also designed to document whether verbal fluency changes impact QOL. Finally, we address the proposal that overall cognitive outcome might be predicted by a combination of attention test findings, age, and dopaminergic medication response prior to surgery.<xref rid="mds26827-bib-0010" ref-type="ref">10</xref>
</p><sec id="mds26827-sec-0006"><title>Patients and Methods</title><sec id="mds26827-sec-0007"><title>Study Design</title><p>Study design and methodology have been previously published.<xref rid="mds26827-bib-0005" ref-type="ref">5</xref> Briefly, patients were randomly assigned in a 3:1 ratio to receive stimulation either immediately (7 days) after device implantation was completed (active stimulation; AS) or 3 months following surgery (delayed activation control; DA). Neuropsychological evaluations were completed at baseline, 3 months after surgery (comparing cognitive changes in AS and DA relative to baseline), and again 12 months after surgery (comparing cognitive change in the combined stimulation [Stim] group compared to baseline).</p></sec><sec id="mds26827-sec-0008"><title>Neuropsychological Evaluation</title><p>Baseline neuropsychological evaluation occurred 1 to 4 weeks prior to surgery. These data served not only as comparison points for the 2 postsurgical evaluations (day 90 and day 365) but also afforded a rigorous confirmation method that patients did not have significant cognitive impairment or untreated depression. It is emphasized that neuropsychological evaluation results at 90 days compared changes between the AS and DA groups relative to baseline, whereas evaluation at 365 days compared the entire group's performance to baseline. Thus, in the 365 day comparison, the majority of patients (the original AS group) had undergone 12 months of stimulation, but a minority (the original DA group) had undergone 9 months of stimulation. When alternate test forms were available, the order in which the forms were administered was randomized. In the case where only 2 alternate forms were available, the baseline and 12&#x02010;month evaluations used the same test form. It is noted that the use of alternate test forms minimizes test&#x02013;retest practice effects, but does not completely eliminate factors such as &#x0201c;test wisdom.&#x0201d; Nonetheless, it is unlikely that test&#x02013;retest influences would mask (or compensate) for cognitive declines when alternate forms are used. Similarly, it is improbable that disease progression would account for declines over 3&#x02010; and 9&#x02010;month test&#x02013;retest intervals given the typically limited change in patients during such an interval.<xref rid="mds26827-bib-0022" ref-type="ref">22</xref>
</p><p>The neuropsychological tests selected evaluated key domains of cognition, including overall level of cognitive function (Dementia Rating Scale&#x02013;2nd edition [DRS&#x02010;2]<xref rid="mds26827-bib-0023" ref-type="ref">23</xref>, attention and working memory (Stroop Color and Word Test <xref rid="mds26827-bib-0024" ref-type="ref">24</xref> and Trailmaking Test<xref rid="mds26827-bib-0025" ref-type="ref">25</xref>, executive functions (Delis&#x02010;Kaplan Executive Function System),<xref rid="mds26827-bib-0026" ref-type="ref">26</xref> verbal fluency tests (Wisconsin Card Sorting Test&#x02013;64 card version<xref rid="mds26827-bib-0027" ref-type="ref">27</xref> and Frontal Systems Behavior Scale<xref rid="mds26827-bib-0028" ref-type="ref">28</xref>, episodic verbal and visual memory (Wechsler Memory Scale, Third Edition, Abbreviated [WMS&#x02010;III&#x02010;A]<xref rid="mds26827-bib-0029" ref-type="ref">29</xref> and Hopkins Verbal Learning Test&#x02013;Revised [HVLT&#x02010;R]<xref rid="mds26827-bib-0030" ref-type="ref">30</xref>, depression (Hamilton Depression Inventory [HDI]<xref rid="mds26827-bib-0031" ref-type="ref">31</xref>, and measures of intelligence (Wechsler Abbreviated Scale of Intelligence [WASI]<xref rid="mds26827-bib-0032" ref-type="ref">32</xref>. WASI and visual confrontation naming (Boston Naming Test)<xref rid="mds26827-bib-0033" ref-type="ref">33</xref> were administered at baseline to characterize the sample and to facilitate dementia screening. Tests were administered in a standard order across all sites.</p></sec><sec id="mds26827-sec-0009"><title>Statistical Analyses</title><p>Sample size was determined so as to allow detection of a 3&#x02010;hour difference in on&#x02010;time without dyskinesias between baseline and follow&#x02010;up with a power of 80% at a statistical significance level of .05, and assuming a 15% dropout rate. Analyses were conducted using the standardized test scores traditionally used in clinical practice. Such scaled scores, <italic>T</italic> scores, and index scores, depending on the test, are corrected for demographic factors such as age, education, and/or gender. The primary neuropsychological analyses comparing change from baseline to 90 days between the AS and DA groups were achieved via analyses of covariance using baseline score and study site as covariates. Because change score analyses between groups do not fully address safety information, these primary analyses were supplemented by within&#x02010;group <italic>t</italic> tests (to determine whether each group's scores had changed significantly from baseline) and by chi&#x02010;square analyses that compared the frequency of changes (no change, decline by 1 standard deviation [SD] or more, improvement by 1 SD or more) in the 2 groups. Changes of 1 SD are typically considered in neuropsychology to be of possible clinical significance. After 90 days, the DA group received active stimulation (after the 3&#x02010;month neuropsychological evaluation) and were evaluated in combination with the AS group at 12 months.</p><p>To determine whether verbal fluency declines influenced satisfaction with communication (per report on the Parkinson's Disease Questionnaire [PDQ&#x02010;39]), independent <italic>t</italic> tests were performed at 12 months to compare mean change in PDQ Communication between verbal fluency decliners and nondecliners. Pearson correlations were used to determine whether statistically significant associations existed between verbal fluency and changes in depression, attention, and levodopa&#x02010;equivalent dosage. To address whether, as shown in a prior study,<xref rid="mds26827-bib-0010" ref-type="ref">10</xref> changes in cognition might be predicted by baseline age, levodopa response, and attention, regression analyses were used with age, baseline levodopa response, and attention composite scores as predictors. Outcome (cognition) was defined in 2 ways. The first was a clinically practical and convenient measure that was the change on a cognitive screening examination (DRS&#x02010;2). The second definition of cognitive outcome was based on a more rigorous neuropsychological test&#x02010;based composite based on change in executive function and memory standardized scores: sum of the standardized Wisconsin Card Sorting Test perseverative errors, letter fluency, semantic fluency, HVLT&#x02010;R total immediate and delayed recall, WMS Logical Memory and Family Pictures immediate and delayed recall scores at 3 months minus the same scores obtained at baseline (note that attention measures were not included so as not to confound outcome and predictors). The predictors were age, baseline percent levodopa response, and a composite of attention and working memory (mean of the standardized Stroop interference and Trailmaking test part B scores).</p></sec></sec><sec id="mds26827-sec-0010"><title>Results</title><p>The demographic and disease characteristics at baseline (see Table <xref rid="mds26827-tbl-0001" ref-type="table-wrap">1</xref>) did not differ significantly between the AS and DA groups.</p><table-wrap id="mds26827-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline demographic and disease characteristics of the stimulation and control groups</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Stimulation, n&#x02009;=&#x02009;101</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control, n&#x02009;=&#x02009;35</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" rowspan="1">Gender</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">63 (62.4)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (60.0)</td><td align="center" rowspan="2" valign="top" colspan="1">.803</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">38 (37.6)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (40.0)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Race</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">White, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">91 (90.1)</td><td align="center" valign="top" rowspan="1" colspan="1">31 (88.6)</td><td align="center" rowspan="4" valign="top" colspan="1">.755<xref ref-type="fn" rid="mds26827-note-0002">a</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">African American, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hispanic, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (7.9)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (8.6)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (2.9)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Age, y</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">60.6 (8.3)</td><td align="center" valign="top" rowspan="1" colspan="1">59.5 (8.2)</td><td align="center" rowspan="2" valign="top" colspan="1">.519</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Range</td><td align="center" valign="top" rowspan="1" colspan="1">41&#x02010;78</td><td align="center" valign="top" rowspan="1" colspan="1">41&#x02010;76</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Years since symptom onset</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">12.1 (4.9)</td><td align="center" valign="top" rowspan="1" colspan="1">11.7 (4.1)</td><td align="center" rowspan="2" valign="top" colspan="1">.684</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Range</td><td align="center" valign="top" rowspan="1" colspan="1">5&#x02010;29</td><td align="center" valign="top" rowspan="1" colspan="1">5&#x02010;19</td></tr></tbody></table><table-wrap-foot><fn id="mds26827-note-0002"><label>a</label><p>White versus nonwhite.</p></fn></table-wrap-foot></table-wrap><p>Levodopa&#x02010;equivalent dosage was significantly reduced from baseline in both groups, but the reduction was significantly greater in the stimulation versus the control group (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001; see Supplemental Table 1). As shown in Table <xref rid="mds26827-tbl-0002" ref-type="table-wrap">2</xref>, there were no significant differences between the stimulation and control groups' baseline neuropsychological test scores. Analyses of covariance on neuropsychological change scores at 3 months did not yield significant interaction terms, but depression symptom severity as measured with the HDI improved significantly only in the stimulation group, yielding a significant group x time interaction (<italic>P</italic>&#x02009;=&#x02009;.005; see Table <xref rid="mds26827-tbl-0002" ref-type="table-wrap">2</xref>). Although the interaction term was not significant, within&#x02010;group <italic>t</italic> tests revealed that both the stimulation and control groups demonstrated significant declines in category and switching verbal fluency (see Figure <xref rid="mds26827-fig-0001" ref-type="fig">1</xref>). The stimulation, but not the control group, showed evidence of significant declines on all parts of the Stroop task and on the letter verbal fluency task. Also unique to the stimulation group were statistically significant increases in the scores for delayed story recall (Logical Memory II) and immediate and delayed recall of pictured scenes (Family Pictures I and II). The control group, but not the stimulation groups, experienced a decline in the DRS initiation/perseveration score.</p><fig fig-type="Figure" xml:lang="en" id="mds26827-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Mean change in verbal fluency in active stimulation and control groups at 3 months.</p></caption><graphic id="nlm-graphic-1" xlink:href="MDS-32-433-g001"/></fig><table-wrap id="mds26827-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Neuropsychological performance at baseline and 3 months in the stimulation and control groups and 12 months, mean (SD)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Stimulation</th><th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Control</th><th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">12 months</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Baseline</th><th align="center" valign="bottom" rowspan="1" colspan="1">3 months</th><th align="center" valign="bottom" rowspan="1" colspan="1">Baseline</th><th align="center" valign="bottom" rowspan="1" colspan="1">3 months</th><th align="center" valign="bottom" rowspan="1" colspan="1">Baseline</th><th align="center" valign="bottom" rowspan="1" colspan="1">Follow&#x02010;Up</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Dementia Rating Scale scaled scores</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Attention</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.9 (2.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.9 (2.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.7 (2.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.9 (2.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11.0 (2.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11.0 (2.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Initiation</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.5 (2.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.1 (2.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.8 (2.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.5 (2.9)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.6 (2.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.0 (2.8)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Construction</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.3 (1.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.4 (1.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.4 (2.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.2 (2.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.4 (1.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.3 (1.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Conceptualization</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.2 (2.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.1 (2.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.1 (2.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.2 (2.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.2 (2.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.6 (2.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Memory</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.1 (3.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.4 (3.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.5 (3.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.3 (2.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.1 (2.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.4 (2.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.4 (2.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.5 (5.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.4 (2.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.2 (3.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.5 (3.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.4 (3.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stroop <italic>T</italic> scores</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Word</td><td align="char" char="." valign="top" rowspan="1" colspan="1">38.8 (11.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">37.4 (10.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39.3 (10.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39.0 (10.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39.1 (10.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">35.3 (11.8)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Color</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39.5 (10.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">37.4 (10.7)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39.0 (9.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">37.7 (10.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39.4 (10.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">35.3 (11.0)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Color&#x02010;Word</td><td align="char" char="." valign="top" rowspan="1" colspan="1">44.4 (9.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">41.5 (9.1)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">44.8 (8.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">42.4 (10.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">44.7 (9.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">41.6 (10.2)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Interference</td><td align="char" char="." valign="top" rowspan="1" colspan="1">47.7 (6.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">45.9 (7.9)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">47.0 (8.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">46.6 (8.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">47.9 (7.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">46.9 (8.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Delis&#x02010;Kaplan Executive Function System scaled scores</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Letter fluency</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.6 (4.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.1 (3.7)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.5 (4.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.6 (4.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.5 (4.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.1 (3.9)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Category fluency</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.6 (3.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.7 (3.6)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.2 (3.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.8 (3.4)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.5 (3.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.6 (3.6)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Switching fluency</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.4 (3.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.2 (4.1)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11.4 (2.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.5 (3.5)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.7 (3.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.0 (3.9)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Switching accuracy</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.2 (3.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.5 (3.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11.1 (2.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.5 (3.3)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.5 (3.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.2 (3.9)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wisconsin Card Sorting Test</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Categories (of 6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.71 (1.50)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.54 (1.58)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.13 (1.41)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.13 (1.45)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.82 (1.49)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.64 (1.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Perservative (errors)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Raw scores</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11.1 (7.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.4 (6.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.5 (6.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.2 (6.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11.1 (7.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.7 (6.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic>T</italic> scores</td><td align="char" char="." valign="top" rowspan="1" colspan="1">46.5 (13.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">47.5 (13.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">46.1 (11.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">49.5 (12.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">46.1 (12.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">48.1 (12.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nonperservative (errors)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Raw scores</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.1 (5.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.2 (6.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">7.8 (5.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.7 (5.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.8 (5.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.8 (6.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic>T</italic> scores</td><td align="char" char="." valign="top" rowspan="1" colspan="1">45.5 (13.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">42.9 (13.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">47.9 (10.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">44.8 (9.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">46.0 (12.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">44.4 (12.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Trailmaking test <italic>T</italic> scores</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Trailmaking A</td><td align="char" char="." valign="top" rowspan="1" colspan="1">44.6 (11.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">43.1 (12.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">41.5 (12.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">40.9 (11.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">43.8 (12.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">42.7 (12.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Trailmaking B</td><td align="char" char="." valign="top" rowspan="1" colspan="1">41.6 (12.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">40.7 (14.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39.2 (12.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">36.7 (15.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">41.6 (11.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">40.3 (14.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hopkins Verbal Learning Test&#x02013;Revised <italic>T</italic> scores</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total recall</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39.1 (11.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">40.0 (11.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">36.8 (11.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">38.9 (10.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">38.5 (11.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39.5 (11.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Delayed recall</td><td align="char" char="." valign="top" rowspan="1" colspan="1">40.5 (12.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39.3 (13.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">38.9 (11.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39.3 (11.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">40.6 (12.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">40.4 (13.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Retention</td><td align="char" char="." valign="top" rowspan="1" colspan="1">44.7 (14.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">42.6 (13.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">42.2 (10.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">44.6 (12.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">44.9 (13.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">44.6 (13.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Recognition</td><td align="char" char="." valign="top" rowspan="1" colspan="1">41.2 (12.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">42.5 (11.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">43.2 (13.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">45.3 (13.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">41.7 (12.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">43.1 (12.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wechsler Memory Scale (III&#x02010;A) scaled scores</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Logical Memory I</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.7 (3.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.9 (3.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.2 (2.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.1 (2.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.9 (3.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.5 (3.2)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Logical Memory II</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.3 (3.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.9 (3.4)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.7 (2.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.9 (3.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.8 (3.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.5 (3.5)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Family Pictures I</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.9 (3.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.6 (3.2)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.8 (2.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.8 (2.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.6 (3.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11.2 (3.3)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Family Pictures II</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.0 (3.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.8 (3.3)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.8 (2.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.2 (3.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.9 (3.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.7 (3.5)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hamilton Depression Inventory <italic>T</italic> score</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total*<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">66.1 (13.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">57.4 (13.7)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">69.3 (13.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">66.2 (11.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">66.9 (13.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">60.2 (14.5)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Frontal Systems Behavior Scale <italic>T</italic> scores</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Apathy</td><td align="char" char="." valign="top" rowspan="1" colspan="1">64.8 (18.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">61.3 (16.1)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">69.0 (16.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">65.8 (14.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">65.5 (17.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">64.8 (16.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Disinhibition</td><td align="char" char="." valign="top" rowspan="1" colspan="1">56.6 (18.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">55.6 (15.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">60.4 (13.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">60.3 (14.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">58.1 (17.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">58.1 (16.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Executive dysfunction</td><td align="char" char="." valign="top" rowspan="1" colspan="1">62.4 (16.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">59.7 (14.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">64.4 (17.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">65.4 (13.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">62.7 (16.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">61.3 (15.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td align="char" char="." valign="top" rowspan="1" colspan="1">64.4 (18.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">61.2 (15.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">68.3 (14.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">66.4 (13.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">65.2 (17.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">63.6 (16.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wechsler Abbreviated Scale of Intelligence <italic>T</italic> scores</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IQ</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">104.9 (17.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">103.7 (16.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vocabulary</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">53.8 (10.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">51.0 (10.8)<xref ref-type="fn" rid="mds26827-note-0004">a</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Matrix reasoning</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">51.6 (12.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">52.0 (11.0)</td></tr></tbody></table><table-wrap-foot><fn id="mds26827-note-0003"><p>IQ, intelligence quotient.</p></fn><fn id="mds26827-note-0004"><label>a</label><p>
<italic>P</italic>&#x02009;&#x0003c;&#x02009;.05 for paired <italic>t</italic> tests addressing change within groups.</p></fn><fn id="mds26827-note-0005"><p>**<italic>P</italic>&#x02009;&#x0003c;&#x02009;.05 for analysis of covariance for group by time, adjusting for site and baseline score.</p></fn></table-wrap-foot></table-wrap><p>The magnitude of the verbal fluency changes was of likely clinical significance (&#x02009;&#x0003e;&#x02009;1 SD decline) in 16% to 40% of the patients, depending on the task (see Supplemental Table 2 and Fig. <xref rid="mds26827-fig-0002" ref-type="fig">2</xref>). In contrast, the Stroop interference score declined in only about 9% of patients in both groups. Mean improvements in the WMS memory scores, despite their statistical significance, were unlikely of clinical significance because 0% of the changes exceeded 1 SD in either direction. Depression score changes of clinical significance (&#x02009;&#x0003e;&#x02009;1 SD improvement) were observed in 30% of the control group and 43% of the stimulation group.</p><fig fig-type="Figure" xml:lang="en" id="mds26827-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Verbal fluency: frequencies of individual change expressed in standard deviations at 3 months. SD, standard deviation.</p></caption><graphic id="nlm-graphic-3" xlink:href="MDS-32-433-g002"/></fig><p>Changes in letter fluency score from baseline to 3 months (in the entire study sample) were not significantly correlated with age or changes on tests of complex attention/working memory (Trailmaking part B, Stroop Interference; all <italic>r</italic>&#x02009;&#x0003c;&#x02009;0.1, <italic>P</italic>&#x02009;&#x0003e;&#x02009;.42). Similarly, category fluency change at 3 months was not significantly correlated with either age or attention/working memory test score changes (all <italic>r</italic>&#x02009;&#x0003c;&#x02009;0.17, <italic>P</italic>&#x02009;&#x0003e;&#x02009;.08), although the association between change in Trailmaking part B and category fluency approached significance (<italic>r</italic>&#x02009;=&#x02009;0.16, <italic>P</italic>&#x02009;=&#x02009;.08). Neither letter (<italic>r</italic>&#x02009;=&#x02009;0.02, <italic>P</italic>&#x02009;=&#x02009;.85) nor category fluency changes (<italic>r</italic>&#x02009;=&#x02009;&#x02212;0.01, <italic>P</italic>&#x02009;=&#x02009;.92) were significantly associated with quality of life (PDQ&#x02010;39 Communication) change. There was only a trend for a negative association between switching fluency declines and changes in PDQ&#x02010;39 Communication scores (<italic>r</italic>&#x02009;=&#x02009;&#x02212;0.22, <italic>P</italic>&#x02009;=&#x02009;.08). Fluency changes were not associated with changes in the medication expressed in levodopa&#x02010;equivalent units (all <italic>r</italic>&#x02009;&#x0003c;&#x02009;0.06, <italic>P</italic>&#x02009;&#x0003e;&#x02009;.52; see Supplemental Table 3).</p><sec id="mds26827-sec-0011"><title>Baseline Predictors of Cognitive Change at 90 Days</title><p>The change in overall level of cognitive functioning (DRS&#x02010;2 total score) was not significantly associated with a combination of baseline levodopa response, age, and an average composite of attention/working memory. A composite of average change on executive and memory tests similarly was not significantly associated with the predictors of levodopa response, age, and attention/working memory. Overall change in cognition (DRS&#x02010;2) was not associated with change in depression score (<italic>r</italic>&#x02009;=&#x02009;0.002; <italic>P</italic>&#x02009;&#x0003e;&#x02009;.98).</p></sec><sec id="mds26827-sec-0012"><title>Neuropsychological Changes From Baseline to 12 Months</title><p>Baseline and 12&#x02010;month scores are shown in Table <xref rid="mds26827-tbl-0002" ref-type="table-wrap">2</xref>. The WASI Vocabulary <italic>T</italic> score declined significantly for the entire sample from baseline (<italic>P</italic>&#x02009;=&#x02009;.004). On the Stroop task, there were significant declines in the word, color, and color&#x02010;word (all <italic>P</italic>&#x02009;&#x0003c;&#x02009;.001) portions, but not on the interference part of the task (<italic>P</italic>&#x02009;=&#x02009;.26). Declines in excess of 1 SD occurred in about 18% of the patients on each of the first 3 parts of the Stroop test (see Supplemental Table 2). The Hamilton Depression Inventory score was significantly lower (improved) at 12 months than at baseline (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.001), with improvements of 1 SD or more seen in 39% of patients. The 4 WMS&#x02010;III&#x02010;A subtest scores all increased from baseline (all <italic>P</italic>&#x02009;&#x0003c;&#x02009;.01), but individually, 0% of patients showed changes exceeding 1 SD. All 3 verbal fluency tasks revealed significant declines at 12 months when compared with baseline (all <italic>P</italic>&#x02009;&#x0003c;&#x02009;.001; see Fig. <xref rid="mds26827-fig-0003" ref-type="fig">3</xref>). Declines greater than 1 SD occurred in 31% of patients in letter fluency, 36% in category fluency, and 43% in switching fluency (see Supplemental Fig. <xref rid="mds26827-fig-0001" ref-type="fig">1</xref>). For the groups showing greater than 1 SD loss versus less than 1 SD loss in verbal fluency scores, only those showing declines greater than 1 SD in letter fluency showed a statistically significance change (greater dissatisfaction) on the PDQ&#x02010;39 Communication scale (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.026) at 12 months (see Supplemental Table 4).</p><fig fig-type="Figure" xml:lang="en" id="mds26827-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Verbal fluency at baseline and 12 months.</p></caption><graphic id="nlm-graphic-5" xlink:href="MDS-32-433-g003"/></fig></sec></sec><sec id="mds26827-sec-0013"><title>Discussion</title><p>The key findings of this study were consistent with the prior literature suggesting that STN DBS is relatively safe from a cognitive standpoint.<xref rid="mds26827-bib-0004" ref-type="ref">4</xref>, <xref rid="mds26827-bib-0007" ref-type="ref">7</xref>, <xref rid="mds26827-bib-0008" ref-type="ref">8</xref>, <xref rid="mds26827-bib-0034" ref-type="ref">34</xref> The majority of cognitive test scores did not reveal significant changes at 3 or 12 months after surgery. There were, however, declines on tests of verbal fluency, processing speed, and attention/working memory. This study adds important information to the existing literature because the delayed stimulation control design of this trial revealed that when changes occurred in cognition, they appeared in both the active stimulation and control groups. Thus, a &#x0201c;microlesion effect&#x0201d; or some other aspect of electrode implantation might underlie some cognitive changes as has been suggested previously.<xref rid="mds26827-bib-0005" ref-type="ref">5</xref>, <xref rid="mds26827-bib-0019" ref-type="ref">19</xref> Importantly, however, such microlesion surgical effects do not completely explain cognitive decline because the letter fluency and Stroop task declines occurred only in the stimulation group. The occurrence of a significant decline in letter fluency in the stimulation but not the control group is unlikely to reflect the larger sample size (and greater statistical power) in the stimulation than control group (patients were randomized in a 3:1 ratio to these groups). Although the effect size of the decline was moderate (d&#x02009;=&#x02009;0.38) in the stimulation group, it was small in the control group (d&#x02009;=&#x02009;0.21). Consequently, although proportions of persons showing less than 1 SD and greater then 1 SD changes in letter fluency were similar in the 2 groups, the decline was larger in the stimulation than in the control group. Similarly, although both effect sizes were small, the decline in the Stroop interference task was greater in the stimulation (d&#x02009;=&#x02009;0.24) than in the control group (d&#x02009;=&#x02009;0.05).</p><p>Consistent with prior studies,<xref rid="mds26827-bib-0011" ref-type="ref">11</xref>, <xref rid="mds26827-bib-0013" ref-type="ref">13</xref> verbal fluency changes of possible clinical significance were common, occurring in 16% to 40% of patients, depending on the verbal fluency task. The exact mechanisms underlying the verbal fluency changes could not be ascertained in this study, but given the changes on the Stroop tasks, factors such as executive function and processing speed likely play a role in these changes. Although a recent study failed to find associations between verbal fluency changes and a few executive function measures,<xref rid="mds26827-bib-0035" ref-type="ref">35</xref> such a proposal is consistent with the notion that fluency tasks, although weakly to moderately associated with executive function measures, address a unique aspect of cognition<xref rid="mds26827-bib-0036" ref-type="ref">36</xref> and consistent with the finding that the executive process of switching between word subcategories during verbal fluency tasks is disrupted following STN DBS.<xref rid="mds26827-bib-0037" ref-type="ref">37</xref> The durability of the verbal fluency decline after STN DBS over 12 months of follow&#x02010;up was consistent with prior work showing that declines may persist up to 5 years after surgery<xref rid="mds26827-bib-0017" ref-type="ref">17</xref> and that the difference in verbal fluency deficits between operated versus nonoperated patients may become more exaggerated over time.<xref rid="mds26827-bib-0018" ref-type="ref">18</xref>
</p><p>Of the significant neuropsychological test score changes, the majority involved declines. However, the 4 WMS&#x02010;III&#x02010;A subtest scores (immediate and delayed recall of pictured scenes and stories) improved in the stimulation group at 90 days. This change may represent practice effects because gains were not observed on other memory tasks (HVLT&#x02010;R) and it was not likely clinically meaningful with no patients experiencing gains exceeding 1 SD.</p><p>One goal of neuropsychological evaluation in DBS candidates is the accurate prediction of which individuals will experience marked cognitive changes during therapeutic stimulation. The metrics to predict these changes have has been poorly defined and have to date failed to provide reliable predictors of which individuals will experience marked cognitive changes (in the absence of operative or perioperative complications). Numerous risk factors have been proposed for cognitive decline, albeit inconsistently, including age older than 69 years,<xref rid="mds26827-bib-0038" ref-type="ref">38</xref>, <xref rid="mds26827-bib-0039" ref-type="ref">39</xref> preoperative cognitive deficit,<xref rid="mds26827-bib-0037" ref-type="ref">37</xref>, <xref rid="mds26827-bib-0040" ref-type="ref">40</xref> higher stimulation frequency,<xref rid="mds26827-bib-0041" ref-type="ref">41</xref> stimulation amplitude and pulse width,<xref rid="mds26827-bib-0042" ref-type="ref">42</xref> stimulation in the anteroventral STN,<xref rid="mds26827-bib-0043" ref-type="ref">43</xref> baseline levodopa dose,<xref rid="mds26827-bib-0039" ref-type="ref">39</xref> and axial symptom severity.<xref rid="mds26827-bib-0039" ref-type="ref">39</xref> Smeding and colleagues<xref rid="mds26827-bib-0010" ref-type="ref">10</xref> reported that baseline neuropsychological&#x02010;, patient&#x02010;, and disease&#x02010;related variables considered in tandem might better predict the risk of overall cognitive decline.<xref rid="mds26827-bib-0010" ref-type="ref">10</xref> Specifically, they reported that attention scores (Stroop and Trailmaking composite), age, and levodopa response best predicted the risk for multivariate&#x02010;defined cognitive decline.<xref rid="mds26827-bib-0010" ref-type="ref">10</xref> Unfortunately, our study, similar to that of Odekerken and colleagues,<xref rid="mds26827-bib-0012" ref-type="ref">12</xref> was not able to replicate this finding using either a cognitive screening measure or a test score composite as outcome. One possible reason for the failure to replicate the findings may be that cognitive outcome was defined differently in the 2 studies.</p><p>Depression symptoms, as measured by the HDI, improved only in the stimulation group at 90 days and remained significantly improved at 12 months in the entire sample. Consequently, it is likely that stimulation might exert a beneficial effect on these symptoms. Whether the effect is generated by directly altering activity in the mesolimbic circuits, or indirectly (because of greater motor symptom relief or levodopa reduction in the stimulated group) is unknown. It should be noted that a significant proportion of patients in the control group also reported improvements in depressive symptoms&#x02014;in this case, it is even more difficult to disentangle direct, indirect, and potential placebo effects. Improvements on self&#x02010;report symptom scales after STN DBS have been previously reported,<xref rid="mds26827-bib-0034" ref-type="ref">34</xref>, <xref rid="mds26827-bib-0044" ref-type="ref">44</xref> but it is important that symptoms of depression are not equivalent to the syndrome of depression or to an index of caseness (ie, the number of persons having the condition of interest).<xref rid="mds26827-bib-0045" ref-type="ref">45</xref> Nonetheless, this study had a low incidence of depression (&#x02009;&#x0003c;&#x02009;1% for serious adverse events across 12 months; 4% in the stimulation group and 9% in the entire sample between 3 and 12 months for nonserious events<xref rid="mds26827-bib-0005" ref-type="ref">5</xref>, indeed at most time points lower than the 7% to 8% figures reported in meta&#x02010;analyses.<xref rid="mds26827-bib-0046" ref-type="ref">46</xref>, <xref rid="mds26827-bib-0047" ref-type="ref">47</xref>
</p><p>In conclusion, STN DBS, using a constant current device, appears to be reasonably cognitively safe, but mild changes in verbal fluency were common and mild declines in processing speed were evidenced. These changes can be attributed to both electrode placement and stimulation. Slight improvements in memory scores were observed, however, they did not exceed those typically expected from practice effects. The incidence of depression up to 1 year after surgery was low, and stimulation improved depressive symptoms. Neurobehavioral changes did not resolve within 12 months following DBS surgery.</p></sec><sec id="mds26827-sec-1015"><title>Acknowledgment</title><p>The authors thank Michael Kutner, Ph.D. for assistance with statistical analyses.</p></sec><sec id="mds26827-sec-0014"><title>Authors Roles</title><p>1. Research Project: A. Conception, B. Organization, C. Execution; 2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 3. Manuscript Preparation: A. Writing the First Draft, B. Review and Critique.</p><p>A.I.T.: 1A, 2A,C, 3A,B</p><p>J.J.: 1A, 2C, 3B</p><p>M.T.: 1A, 2C, 3B</p><p>D.P.: 1A,B,C, 2C, 3B</p><p>M.S.O.: 1A, 2C, 3B</p></sec><sec id="mds26827-sec-0114"><title>Full financial disclosure for the previous 12 months</title><p>Drs. A.I.T. and M.T. are paid consultants for St. Jude Medical. A.I.T. has served as a consultant and/or on the scientific advisory boards for Medtronic, Boston Scientific, Teva, Takeda, Theravance, and Pfizer. He has received grant/research support support from National Institutes of Health, the Michael J. Fox Foundation, the Barrow Neurological Foundation, Glaxo Smith Kline, and Medtronic. A.I.T. has received book royalties from Cambridge University Press and Oxford University Press. M.T. has received honoraria from Medtronic Inc. J.J. is a consultant for Allergan, Chelsea Therapeutics, EMD Serono, Lundbeck Inc., Merz Pharmaceuticals, and Teva Pharmaceutical Industries Ltd; has received grants from Allergan, Allon Therapeutics, Ceregene Inc., Chelsea Therapeutics, Diana Helis Henry Medical Research Foundation, EMD Serono, Huntington's Disease Society of America, Huntington Study Group, Impax Pharmaceuticals, Ipsen Limited, Lundbeck Inc., Michael J. Fox Foundation for Parkinson Research, Medtronic, Merz Pharmaceuticals, National Institutes of Health, National Parkinson Foundation, Neurogen, St. Jude Medical Neuromodulation Division, Teva Pharmaceutical Industries Ltd, University of Rochester, and the Parkinson Study Group; and has received royalties from Elsevier, Lippincott Williams and Wilkins, and UpToDate. M.S.O. serves as a consultant for the National Parkinson Foundation and has received research grants from National Institutes of Health, National Parkinson Foundation, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann&#x02010;Strauss Foundation, the Tourette Syndrome Association, and the University of Florida Foundation. M.S.O. has previously received honoraria, but in the past &#x0003e;60 months has received no support from industry. M.S.O. has received royalties for publications with Demos, Manson, Amazon, Smashwords, Books4Patients, and Cambridge (movement disorders books). M.S.O. is an associate editor for the <italic>New England Journal of Medicine Journal Watch Neurology</italic>. M.S.O. has participated in Continuing Medical Education and educational activities on movement disorders (in the past 36) months sponsored by PeerView, Prime, Quantia, Henry Stewart, and by Vanderbilt University. The institution and not M.S.O. receives grants from Medtronic, Abbvie, and Adanced Neuromodulation Systems/St. Jude, and the PI has no financial interest in these grants. M.S.O. has participated as a site principal investigator and/or co&#x02010;investigator for several National Institutes of Health, foundation, and industry sponsored trials over the years but has not received honoraria. D.P. is an employee of St. Jude Medical Inc.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><p>Additional Supporting Information may be found in the online version of this article at the publisher's web&#x02010;site.</p></supplementary-material><supplementary-material content-type="local-data"><caption><p>Supplementary Information Figure 1.</p></caption><media xlink:href="MDS-32-433-s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>Supplementary Information Table 1.</p></caption><media xlink:href="MDS-32-433-s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>Supplementary Information Table 2.</p></caption><media xlink:href="MDS-32-433-s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>Supplementary Information Table 3.</p></caption><media xlink:href="MDS-32-433-s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>Supplementary Information Table 4.</p></caption><media xlink:href="MDS-32-433-s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references"><title>References</title><ref id="mds26827-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="mds26827-cit-0001">
<string-name>
<surname>Deuschl</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Schade&#x02010;Brittinger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Krack</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>A randomized trial of deep&#x02010;brain stimulation for Parkinson's disease</article-title>. <source>N Engl J Med</source>
<year>2006</year>;<volume>355</volume>(<issue>9</issue>):<fpage>896</fpage>&#x02013;<lpage>908</lpage>.
<pub-id pub-id-type="pmid">16943402</pub-id></mixed-citation></ref><ref id="mds26827-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="mds26827-cit-0002">
<string-name>
<surname>Weaver</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Follett</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Stern</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial</article-title>. <source>JAMA</source>
<year>2009</year>;<volume>301</volume>(<issue>1</issue>):<fpage>63</fpage>&#x02013;<lpage>73</lpage>.
<pub-id pub-id-type="pmid">19126811</pub-id></mixed-citation></ref><ref id="mds26827-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="mds26827-cit-0003">
<string-name>
<surname>Williams</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gill</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Varma</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open&#x02010;label trial</article-title>. <source>Lancet Neurol</source>
<year>2010</year>;<volume>9</volume>(<issue>6</issue>):<fpage>581</fpage>&#x02013;<lpage>591</lpage>.
<pub-id pub-id-type="pmid">20434403</pub-id></mixed-citation></ref><ref id="mds26827-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="mds26827-cit-0004">
<string-name>
<surname>Schuepbach</surname>
<given-names>WM</given-names>
</string-name>, <string-name>
<surname>Rau</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Knudsen</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Neurostimulation for Parkinson's disease with early motor complications</article-title>. <source>N Engl J Med</source>
<year>2013</year>;<volume>368</volume>(<issue>7</issue>):<fpage>610</fpage>&#x02013;<lpage>622</lpage>.
<pub-id pub-id-type="pmid">23406026</pub-id></mixed-citation></ref><ref id="mds26827-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="mds26827-cit-0005">
<string-name>
<surname>Okun</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Gallo</surname>
<given-names>BV</given-names>
</string-name>, <string-name>
<surname>Mandybur</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Subthalamic deep brain stimulation with a constant&#x02010;current device in Parkinson's disease: an open&#x02010;label randomised controlled trial</article-title>. <source>Lancet Neurol</source>
<year>2012</year>;<volume>11</volume>(<issue>2</issue>):<fpage>140</fpage>&#x02013;<lpage>149</lpage>.
<pub-id pub-id-type="pmid">22239915</pub-id></mixed-citation></ref><ref id="mds26827-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="mds26827-cit-0006">
<string-name>
<surname>Follett</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Weaver</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Stern</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Pallidal versus subthalamic deep&#x02010;brain stimulation for Parkinson's disease</article-title>. <source>N Engl J Med</source>
<year>2010</year>;<volume>362</volume>(<issue>22</issue>):<fpage>2077</fpage>&#x02013;<lpage>2091</lpage>.
<pub-id pub-id-type="pmid">20519680</pub-id></mixed-citation></ref><ref id="mds26827-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="mds26827-cit-0007">
<string-name>
<surname>Weaver</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Follett</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Stern</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Randomized trial of deep brain stimulation for Parkinson disease: thirty&#x02010;six&#x02010;month outcomes</article-title>. <source>Neurology</source>
<year>2012</year>;<volume>79</volume>(<issue>1</issue>):<fpage>55</fpage>&#x02013;<lpage>65</lpage>.
<pub-id pub-id-type="pmid">22722632</pub-id></mixed-citation></ref><ref id="mds26827-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="mds26827-cit-0008">
<string-name>
<surname>Witt</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Daniels</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Reiff</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study</article-title>. <source>Lancet Neurol</source>
<year>2008</year>;<volume>7</volume>(<issue>7</issue>):<fpage>605</fpage>&#x02013;<lpage>614</lpage>.
<pub-id pub-id-type="pmid">18538636</pub-id></mixed-citation></ref><ref id="mds26827-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="mds26827-cit-0009">
<string-name>
<surname>Combs</surname>
<given-names>HL</given-names>
</string-name>, <string-name>
<surname>Folley</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Berry</surname>
<given-names>DT</given-names>
</string-name>, et al. <article-title>Cognition and depression following deep brain stimulation of the subthalamic nucleus and globus pallidus pars internus in Parkinson's disease: a meta&#x02010;analysis</article-title>. <source>Neuropsychol Rev</source>
<year>2015</year>;<volume>25</volume>(<issue>4</issue>):<fpage>439</fpage>&#x02013;<lpage>454</lpage>.
<pub-id pub-id-type="pmid">26459361</pub-id></mixed-citation></ref><ref id="mds26827-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="mds26827-cit-0010">
<string-name>
<surname>Smeding</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Speelman</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Huizenga</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Schuurman</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Schmand</surname>
<given-names>B</given-names>
</string-name>. <article-title>Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2011</year>;<volume>82</volume>(<issue>7</issue>):<fpage>754</fpage>&#x02013;<lpage>760</lpage>.
<pub-id pub-id-type="pmid">19465417</pub-id></mixed-citation></ref><ref id="mds26827-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="mds26827-cit-0011">
<string-name>
<surname>Odekerken</surname>
<given-names>VJ</given-names>
</string-name>, <string-name>
<surname>van Laar</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Staal</surname>
<given-names>MJ</given-names>
</string-name>, et al. <article-title>Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial</article-title>. <source>Lancet Neurol</source>
<year>2013</year>;<volume>12</volume>(<issue>1</issue>):<fpage>37</fpage>&#x02013;<lpage>44</lpage>.
<pub-id pub-id-type="pmid">23168021</pub-id></mixed-citation></ref><ref id="mds26827-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="mds26827-cit-0012">
<string-name>
<surname>Odekerken</surname>
<given-names>VJ</given-names>
</string-name>, <string-name>
<surname>Boel</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Geurtsen</surname>
<given-names>GJ</given-names>
</string-name>, et al. <article-title>Neuropsychological outcome after deep brain stimulation for Parkinson disease</article-title>. <source>Neurology</source>
<year>2015</year>;<volume>84</volume>(<issue>13</issue>):<fpage>1355</fpage>&#x02013;<lpage>1361</lpage>.
<pub-id pub-id-type="pmid">25724233</pub-id></mixed-citation></ref><ref id="mds26827-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="mds26827-cit-0013">
<string-name>
<surname>Parsons</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Rogers</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Braaten</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Woods</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Tr&#x000f6;ster</surname>
<given-names>AI</given-names>
</string-name>. <article-title>Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta&#x02010;analysis</article-title>. <source>Lancet Neurol</source>
<year>2006</year>;<volume>5</volume>(<issue>7</issue>):<fpage>578</fpage>&#x02013;<lpage>588</lpage>.
<pub-id pub-id-type="pmid">16781988</pub-id></mixed-citation></ref><ref id="mds26827-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="mds26827-cit-0014">
<string-name>
<surname>Rothlind</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>York</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Carlson</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Neuropsychological changes following deep brain stimulation surgery for Parkinson's disease: comparisons of treatment at pallidal and subthalamic targets versus best medical therapy</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2015</year>;<volume>86</volume>(<issue>6</issue>):<fpage>622</fpage>&#x02013;<lpage>629</lpage>.
<pub-id pub-id-type="pmid">25185211</pub-id></mixed-citation></ref><ref id="mds26827-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="mds26827-cit-0015">
<string-name>
<surname>Fields</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Tr&#x000f6;ster</surname>
<given-names>AI</given-names>
</string-name>. <article-title>Cognitive outcomes after deep brain stimulation for Parkinson's disease: a review of initial studies and recommendations for future research</article-title>. <source>Brain and Cogn</source>
<year>2000</year>;<volume>42</volume>(<issue>2</issue>):<fpage>268</fpage>&#x02013;<lpage>293</lpage>.
</mixed-citation></ref><ref id="mds26827-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="mds26827-cit-0016">
<string-name>
<surname>Funkiewiez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ardouin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Caputo</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2004</year>;<volume>75</volume>(<issue>6</issue>):<fpage>834</fpage>&#x02013;<lpage>839</lpage>.
<pub-id pub-id-type="pmid">15145995</pub-id></mixed-citation></ref><ref id="mds26827-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="mds26827-cit-0017">
<string-name>
<surname>Contarino</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Daniele</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sibilia</surname>
<given-names>AH</given-names>
</string-name>, et al. <article-title>Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2007</year>;<volume>78</volume>(<issue>3</issue>):<fpage>248</fpage>&#x02013;<lpage>252</lpage>.
<pub-id pub-id-type="pmid">16690696</pub-id></mixed-citation></ref><ref id="mds26827-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="mds26827-cit-0018">
<string-name>
<surname>Fasano</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Romito</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Daniele</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants</article-title>. <source>Brain</source>
<year>2010</year>;<volume>133</volume>(<issue>9</issue>):<fpage>2664</fpage>&#x02013;<lpage>2676</lpage>.
<pub-id pub-id-type="pmid">20802207</pub-id></mixed-citation></ref><ref id="mds26827-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="mds26827-cit-0019">
<string-name>
<surname>Okun</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Fernandez</surname>
<given-names>HH</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>SS</given-names>
</string-name>, et al. <article-title>Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial</article-title>. <source>Ann Neurol</source>
<year>2009</year>;<volume>65</volume>(<issue>5</issue>):<fpage>586</fpage>&#x02013;<lpage>595</lpage>.
<pub-id pub-id-type="pmid">19288469</pub-id></mixed-citation></ref><ref id="mds26827-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="mds26827-cit-0020">
<string-name>
<surname>Wojtecki</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Timmermann</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Jorgens</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Frequency&#x02010;dependent reciprocal modulation of verbal fluency and motor functions in subthalamic deep brain stimulation</article-title>. <source>Arch Neurol</source>
<year>2006</year>;<volume>63</volume>(<issue>9</issue>):<fpage>1273</fpage>&#x02013;<lpage>1276</lpage>.
<pub-id pub-id-type="pmid">16966504</pub-id></mixed-citation></ref><ref id="mds26827-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="mds26827-cit-0021">
<string-name>
<surname>Saez&#x02010;Zea</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Escamilla&#x02010;Sevilla</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Katati</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Minguez&#x02010;Castellanos</surname>
<given-names>A</given-names>
</string-name>. <article-title>Cognitive effects of subthalamic nucleus stimulation in Parkinson's disease: a controlled study</article-title>. <source>Eur Neurol</source>
<year>2012</year>;<volume>68</volume>(<issue>6</issue>):<fpage>361</fpage>&#x02013;<lpage>366</lpage>.
<pub-id pub-id-type="pmid">23095782</pub-id></mixed-citation></ref><ref id="mds26827-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="mds26827-cit-0022">
<string-name>
<surname>Tr&#x000f6;ster</surname>
<given-names>AI</given-names>
</string-name>, <string-name>
<surname>Woods</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Morgan</surname>
<given-names>EE</given-names>
</string-name>. <article-title>Assessing cognitive change in Parkinson's disease: development of practice effect&#x02010;corrected reliable change indices</article-title>. <source>Arch Clin Neuropsychol</source>
<year>2007</year>;<volume>22</volume>(<issue>6</issue>):<fpage>711</fpage>&#x02013;<lpage>718</lpage>.
<pub-id pub-id-type="pmid">17644304</pub-id></mixed-citation></ref><ref id="mds26827-bib-0023"><label>23</label><mixed-citation publication-type="book" id="mds26827-cit-0023">
<string-name>
<surname>Mattis</surname>
<given-names>S</given-names>
</string-name>. <source>Dementia Rating Scale&#x02010;2</source>. <publisher-loc>Lutz, FL</publisher-loc>: <publisher-name>Psychological Assessment Resources, Inc</publisher-name>; <year>2001</year>.
</mixed-citation></ref><ref id="mds26827-bib-0024"><label>24</label><mixed-citation publication-type="book" id="mds26827-cit-0024">
<string-name>
<surname>Golden</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Freshwater</surname>
<given-names>SM</given-names>
</string-name>. <source>Stroop Color and Word Test: A Manual for Clinical and Experimental Uses</source>. <publisher-loc>Wood Dale, IL</publisher-loc>: <publisher-name>Stoelting</publisher-name>; <year>2002</year>.
</mixed-citation></ref><ref id="mds26827-bib-0025"><label>25</label><mixed-citation publication-type="book" id="mds26827-cit-0025">
<string-name>
<surname>Reitan</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Wolfson</surname>
<given-names>D</given-names>
</string-name>. <source>The Halstead&#x02010;Reitan Neuropsychological Test Battery</source>. <publisher-loc>Tucson, AZ</publisher-loc>: <publisher-name>Neuropsychology Press</publisher-name>; <year>1985</year>.
</mixed-citation></ref><ref id="mds26827-bib-0026"><label>26</label><mixed-citation publication-type="book" id="mds26827-cit-0026">
<string-name>
<surname>Delis</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Kaplan</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kramer</surname>
<given-names>JH</given-names>
</string-name>. <source>Delis&#x02010;Kaplan Executive Function System (D&#x02010;KEFS)</source>. <publisher-loc>San Antonio, TX</publisher-loc>: <publisher-name>The Psychological Corporation</publisher-name>; <year>2001</year>.
</mixed-citation></ref><ref id="mds26827-bib-0027"><label>27</label><mixed-citation publication-type="book" id="mds26827-cit-0027">
<string-name>
<surname>Kongs</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Iverson</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Heaton</surname>
<given-names>RK</given-names>
</string-name>. <source>Wisconsin Card Sorting Test&#x02013;64 Card Version</source>. <publisher-loc>Odessa, FL</publisher-loc>: <publisher-name>Psychological Assessment Resources</publisher-name>; <year>2000</year>.
</mixed-citation></ref><ref id="mds26827-bib-0028"><label>28</label><mixed-citation publication-type="book" id="mds26827-cit-0028">
<string-name>
<surname>Grace</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Malloy</surname>
<given-names>PF</given-names>
</string-name>. <source>Frontal Systems Behavior Scale: Professional Manual</source>. <publisher-loc>Lutz, FL</publisher-loc>: <publisher-name>Psychological Assessment Resources, Inc</publisher-name>; <year>2001</year>.
</mixed-citation></ref><ref id="mds26827-bib-0029"><label>29</label><mixed-citation publication-type="book" id="mds26827-cit-0029">
<string-name>
<surname>Wechsler</surname>
<given-names>D</given-names>
</string-name>. <source>Wechsler Memory Scale, Third Edition, Abbreviated</source>. <publisher-loc>San Antonio, TX</publisher-loc>: <publisher-name>Psychological Corporation</publisher-name>; <year>1997</year>.
</mixed-citation></ref><ref id="mds26827-bib-0030"><label>30</label><mixed-citation publication-type="book" id="mds26827-cit-0030">
<string-name>
<surname>Brandt</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Benedict</surname>
<given-names>RH</given-names>
</string-name>. <source>The Hopkins Verbal Learning Test&#x02013;Revised</source>. <publisher-loc>Lutz, FL</publisher-loc>: <publisher-name>Psychological Assessment Resources, Inc</publisher-name>; <year>2001</year>.
</mixed-citation></ref><ref id="mds26827-bib-0031"><label>31</label><mixed-citation publication-type="book" id="mds26827-cit-0031">
<string-name>
<surname>Reynolds</surname>
<given-names>WM</given-names>
</string-name>, <string-name>
<surname>Kobak</surname>
<given-names>KA</given-names>
</string-name>. <source>Hamilton Depression Inventory&#x02013;A Self&#x02010;Report Version of the Hamilton Depression Rating Scale (HDRS)</source>. <publisher-loc>Odessa, FL</publisher-loc>: <publisher-name>Psychological Assessment Resources</publisher-name>; <year>1995</year>.
</mixed-citation></ref><ref id="mds26827-bib-0032"><label>32</label><mixed-citation publication-type="book" id="mds26827-cit-0032">
<string-name>
<surname>Wechsler</surname>
<given-names>D</given-names>
</string-name>. <source>Wechsler Abbreviated Scale of Intellience</source>. <publisher-loc>San Antonio, TX</publisher-loc>: <publisher-name>The Psychological Corporation</publisher-name>; <year>1999</year>.
</mixed-citation></ref><ref id="mds26827-bib-0033"><label>33</label><mixed-citation publication-type="book" id="mds26827-cit-0033">
<string-name>
<surname>Kaplan</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Goodglass</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Weintraub</surname>
<given-names>S</given-names>
</string-name>. <source>Boston Naming Test</source>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Lea &#x00026; Febiger</publisher-name>; <year>1983</year>.
</mixed-citation></ref><ref id="mds26827-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="mds26827-cit-0034">
<string-name>
<surname>Ardouin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pillon</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Peiffer</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients</article-title>. <source>Ann Neurol</source>
<year>1999</year>;<volume>46</volume>(<issue>2</issue>):<fpage>217</fpage>&#x02013;<lpage>223</lpage>.
<pub-id pub-id-type="pmid">10443887</pub-id></mixed-citation></ref><ref id="mds26827-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="mds26827-cit-0035">
<string-name>
<surname>Houvenaghel</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Le Jeune</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Dondaine</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Reduced verbal fluency following subthalamic deep brain stimulation: a frontal&#x02010;related cognitive deficit?</article-title>
<source>PLoS ONE</source>
<year>2015</year>;<volume>10</volume>(<issue>10</issue>):<fpage>e0140083</fpage>.
<pub-id pub-id-type="pmid">26448131</pub-id></mixed-citation></ref><ref id="mds26827-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="mds26827-cit-0036">
<string-name>
<surname>Piatt</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Fields</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Paolo</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Tr&#x000f6;ster</surname>
<given-names>AI</given-names>
</string-name>. <article-title>Action (verb naming) fluency as an executive function measure: convergent and divergent evidence of validity</article-title>. <source>Neuropsychologia</source>
<year>1999</year>;<volume>37</volume>:<fpage>1499</fpage>&#x02013;<lpage>1503</lpage>.
<pub-id pub-id-type="pmid">10617270</pub-id></mixed-citation></ref><ref id="mds26827-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="mds26827-cit-0037">
<string-name>
<surname>De Gaspari</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Siri</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Di Gioia</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Clinical correlates and cognitive underpinnings of verbal fluency impairment after chronic subthalamic stimulation in Parkinson's disease</article-title>. <source>Parkinsonism Relat Disord</source>
<year>2006</year>;<volume>12</volume>(<issue>5</issue>):<fpage>289</fpage>&#x02013;<lpage>295</lpage>.
<pub-id pub-id-type="pmid">16554183</pub-id></mixed-citation></ref><ref id="mds26827-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="mds26827-cit-0038">
<string-name>
<surname>Saint&#x02010;Cyr</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Tr&#x000e9;panier</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lozano</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Lang</surname>
<given-names>AE</given-names>
</string-name>. <article-title>Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease</article-title>. <source>Brain</source>
<year>2000</year>;<volume>123</volume>(<issue>Pt 10</issue>):<fpage>2091</fpage>&#x02013;<lpage>2108</lpage>.
<pub-id pub-id-type="pmid">11004126</pub-id></mixed-citation></ref><ref id="mds26827-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="mds26827-cit-0039">
<string-name>
<surname>Daniels</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Krack</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Volkmann</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease</article-title>. <source>Mov Disord</source>
<year>2010</year>;<volume>25</volume>(<issue>11</issue>):<fpage>1583</fpage>&#x02013;<lpage>1589</lpage>.
<pub-id pub-id-type="pmid">20589868</pub-id></mixed-citation></ref><ref id="mds26827-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="mds26827-cit-0040">
<string-name>
<surname>Hariz</surname>
<given-names>MI</given-names>
</string-name>, <string-name>
<surname>Johansson</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Shamsgovara</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Johansson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hariz</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Fagerlund</surname>
<given-names>M</given-names>
</string-name>. <article-title>Bilateral subthalamic nucleus stimulation in a parkinsonian patient with preoperative deficits in speech and cognition: persistent improvement in mobility but increased dependency: a case study</article-title>. <source>Mov Disord</source>
<year>2000</year>;<volume>15</volume>(<issue>1</issue>):<fpage>136</fpage>&#x02013;<lpage>139</lpage>.
<pub-id pub-id-type="pmid">10634253</pub-id></mixed-citation></ref><ref id="mds26827-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="mds26827-cit-0041">
<string-name>
<surname>Francel</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ryder</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wetmore</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Deep brain stimulation for Parkinson's disease: association between stimulation parameters and cognitive performance</article-title>. <source>Stereotact Funct Neurosurg</source>
<year>2004</year>;<volume>82</volume>(<issue>4</issue>):<fpage>191</fpage>&#x02013;<lpage>193</lpage>.
<pub-id pub-id-type="pmid">15557768</pub-id></mixed-citation></ref><ref id="mds26827-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="mds26827-cit-0042">
<string-name>
<surname>Schoenberg</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Mash</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Bharucha</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Francel</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Deep brain stimulation parameters associated with neuropsychological changes in subthalamic nucleus stimulation for refractory Parkinson's disease</article-title>. <source>Stereotact Funct Neurosurg</source>
<year>2008</year>;<volume>86</volume>(<issue>6</issue>):<fpage>337</fpage>&#x02013;<lpage>344</lpage>.
<pub-id pub-id-type="pmid">18854660</pub-id></mixed-citation></ref><ref id="mds26827-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="mds26827-cit-0043">
<string-name>
<surname>Tsai</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>SZ</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>SY</given-names>
</string-name>. <article-title>Neuropsychological effects after chronic subthalamic stimulation and the topography of the nucleus in Parkinson's disease</article-title>. <source>Neurosurgery</source>
<year>2007</year>;<volume>61</volume>(<issue>5</issue>):<fpage>E1024</fpage>&#x02013;<lpage>E1029</lpage>; discussion E1029&#x02010;E1030.
<pub-id pub-id-type="pmid">18091257</pub-id></mixed-citation></ref><ref id="mds26827-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="mds26827-cit-0044">
<string-name>
<surname>Kalteis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Standhardt</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kryspin&#x02010;Exner</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Brucke</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Volc</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Alesch</surname>
<given-names>F</given-names>
</string-name>. <article-title>Influence of bilateral Stn&#x02010;stimulation on psychiatric symptoms and psychosocial functioning in patients with Parkinson's disease</article-title>. <source>J Neural Transm</source>
<year>2006</year>;<volume>113</volume>(<issue>9</issue>):<fpage>1191</fpage>&#x02013;<lpage>1206</lpage>.
<pub-id pub-id-type="pmid">16362628</pub-id></mixed-citation></ref><ref id="mds26827-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="mds26827-cit-0045">
<string-name>
<surname>Burn</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Tr&#x000f6;ster</surname>
<given-names>AI</given-names>
</string-name>. <article-title>Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease</article-title>. <source>J Geriatr Psychiatry Neurol</source>
<year>2004</year>;<volume>17</volume>(<issue>3</issue>):<fpage>172</fpage>&#x02013;<lpage>180</lpage>.
<pub-id pub-id-type="pmid">15312281</pub-id></mixed-citation></ref><ref id="mds26827-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="mds26827-cit-0046">
<string-name>
<surname>Kleiner&#x02010;Fisman</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Herzog</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fisman</surname>
<given-names>DN</given-names>
</string-name>, et al. <article-title>Subthalamic nucleus deep brain stimulation: summary and meta&#x02010;analysis of outcomes</article-title>. <source>Mov Disord</source>
<year>2006</year>;<volume>21</volume>(<issue>suppl 14</issue>):<fpage>S290</fpage>&#x02013;<lpage>S304</lpage>.
<pub-id pub-id-type="pmid">16892449</pub-id></mixed-citation></ref><ref id="mds26827-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="mds26827-cit-0047">
<string-name>
<surname>Temel</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kessels</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Topdag</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Boon</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Visser&#x02010;Vandewalle</surname>
<given-names>V</given-names>
</string-name>. <article-title>Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review</article-title>. <source>Parkinsonism Relat Disord</source>
<year>2006</year>;<volume>12</volume>(<issue>5</issue>):<fpage>265</fpage>&#x02013;<lpage>272</lpage>.
<pub-id pub-id-type="pmid">16621661</pub-id></mixed-citation></ref></ref-list></back></article>